Source: Eur Respir J, 50 (3) 1701370; 10.1183/13993003.01370-2017
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Lewis J. Rubin. Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension. Eur Respir J, 50 (3) 1701370; 10.1183/13993003.01370-2017

Member's Comments

No comment yet.

Related content which might interest you: Mutations in the bone morphogenic protein receptor 2 promoter in heritable pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension Source: Eur Respir J 2009; 34: 1100-1110 Year: 2009 Dysregulated bone morphogenetic protein signaling in pulmonary arterial hypertension Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 The adverse effect of estrogen on bone morphogenetic protein receptor (BMPR) signal pathway in pulmonary arterial endothelial cells (PAEC) Source: Annual Congress 2009 - Pulmonary circulation II Year: 2009 Decreased expression of the TGF-beta type I receptor ALK1 in pulmonary arterial hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Bone morphogenetic protein receptor-II as a regulator of pulmonary artery endothelial cell permeability: Relevance to the initiation and progression of heritable pulmonary arterial hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 The microRNA cluster 17/92 regulates the expression of the bone morphogenetic protein receptor type II involved in the pathogenesis of pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension Year: 2009 Genetics of pulmonary hypertension: from bench to bedside Source: Eur Respir J 2002; 20: 741-749 Year: 2002 Pathobiology of pulmonary arterial hypertension and right ventricular failure Source: Eur Respir J 2012; 40: 1555-1565 Year: 2012 Pharmacological activation of Nur77 enhances BMP signalling and inhibits vascular remodelling in pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives Source: Eur Respir J 2002; 20: 518-523 Year: 2002 Regulation of Type I cytokine receptors as a target for pulmonary arterial hypertension treatment? Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Targeting BMPR-II in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches Year: 2016 Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008 Oral presentation: The bone morphogenetic protein antagonist Gremlin in pulmonary hypertension Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis Year: 2009 BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease Source: Eur Respir J 2004; 24: 371-374 Year: 2004 Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females Source: Eur Respir J 2009; 34: 1093-1099 Year: 2009 Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Source: Eur Respir J 2011; 37: 813-822 Year: 2011 NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018